HAIFA, Israel, Sept. 5, 2023 /PRNewswire/ -- ViAqua Therapeutics, a biotechnology company and developer of an orally administered RNA-particle platform to promote and improve animal health in aquaculture, announced it has completed a US$8.25M round led by S2G Ventures with participation from Rabo Ventures, The Trendlines Group Ltd., Agriline Limited, Nutreco, I-Lab Angels and Circle Investments LLC.

Thai Union Group PCL has invested in biotechnology company ViAqua Therapeutics through its venture fund, joining other industry-leading strategic and financial partners in backing the start-up. At left: Thai Union Group PCL CEO Thiraphong Chansiri

​

News of this announcement also appeared on —

• European Supermarket Magazine

• Kaohoon.com

• Prachachat.com

Financing will support the commercialization of the first product aimed at improving health in shrimp and support the development of additional products to improve aquatic animal health and nutrition.

​

News of this announcement also appeared in —

• AgReads | Aquafeed.com  

• Hatchery Feed & Management

• The Fish Site | The Times of Israel

• undercurrentnews

ViAqua mentioned in fireside chat with Nutreco's Chief Strategy Officer Laurent Genet.   

ViAqua mentioned by Joost Matthijssen, Investment Director at Nutreco, at the GrowingIL and Start-Up Nation Central's Annual AgriFood-Tech Global Investors Summit. 

Nutreco has invested in Israeli startup ViAqua as part of its focus on combatting disease in the aquaculture industry. ViAqua is developing the first orally-administered treatment for shrimp that improves resistance to viral diseases, including White Spot Syndrome Virus (WSSV), and prevents viral epidemics. Nutreco has taken a meaningful minority share that will conditionally grow over time.

Singapore-based VisVires New Protein Invests in Israeli startup ViAqua to combat viral infections in aquaculture.